78 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia and skin
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse … fails to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes chronic tendon injuries resulting from sports-related
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical … to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes that chronic tendon injuries resulting from sports-related
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
cellular deficits including chronic tendon injuries, androgenetic alopecia and skin aging.
The Company's corporate office and principal place
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
presented in such statements or disclosures may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports … -
Treatment
The Company believes that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical need
6-K
EX-99.1
hpl4x
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
v5u27cnchgd4yk2z8no
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
d2w24jkrdb
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
y8ij17r
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
df06r
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.2
dgva 7uwl
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
r79xnb
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.3
8o9rkqzp5y
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
3f5qy 79tgkw8
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
h21xzf2uqlfqv4plvis
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
7uv67zt8tb48vy
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
g1czg03
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.2
gq551z90eb75iv95q
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm